Back to Feed
总结
诺和诺德股价在最新交易日上涨约5%，市场焦点转向其Wegovy减重药推出口服剂型后的上市进展。多家媒体援引公司与第三方追踪数据称，产品在上市最初几天已记录约3071张处方，显示启动表现“稳健”。由于此前减重治疗多以注射剂为主，口服方案被认为可能提升用药便利性、改善依从性并降低部分患者的使用门槛与费用预期，从而扩大潜在需求并带动投资者对公司增长与估值的乐观情绪；但后续放量仍取决于定价、报销与供应等因素。
正文
Novo Nordisk shares rise 5% after Wegovy obesity pill has 'solid' launch CNBC Lubbock Doctor compares weight loss injections to new pills KCBD Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch Reuters Wegovy's new pill option could be cheaper for patients. Here's what doctors say WCPO 9 Cincinnati Novo Nordisk's Wegovy Weight Loss Pill Has a Strong Launch-and Other Reasons the Stock Is Rising Barron's
发布时间：